Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes
Main finding · TIRResult — go to the resultIncrease 11 %-pointsAuthors' conclusion
Glycemic control improved within 9 days of Omnipod 5 initiation in this real-world cohort, and improvements were sustained over the first 90 days of use despite concomitant decreases in user-initiated boluses.
Study context
- Population
- Youth 2–21 years with T1D initiating Omnipod 5 at two pediatric academic centers; 78.9% non-Hispanic White, 15.4% publicly insured, age 11.7 years, T1D duration 3.3 years
- Participants
- 195 participants
- Exposure
- First 90 days of Omnipod 5 use vs 14-day baseline continuous glucose monitoring (CGM)
- Outcome
- Change in TIR, hemoglobin A1c (HbA1c), and CGM and insulin pump metrics
- Follow-up
- First 90 days
Methodological detailsreal-world, two pediatric academic centers, before-after comparison
- Real-world
- Two pediatric academic centers
- Before-after comparison
Main finding
TIR
Increase
11 %-points
P < 0.001
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
HbA1c · first 90 days · lower with Omnipod 5
decrease 0.5 · P < 0.001
Time in range (TIR) time course · days 1-9 to days 1-90
- TIR improved within first 9 days of Omnipod 5 use (p < 0.001)
- TIR did not change significantly thereafter (P = 0.1)
User-initiated boluses and carbohydrate entries, days 1-9 vs days 1-90
- User-initiated boluses decreased (P = 0.01)
- 5.1 vs. 5.0
- Carbohydrate entries decreased (P = 0.005)
- 4.2 vs. 4.1
TIR improvement by baseline (BL) TIR subgroup
- TIR improvement, BL TIR <60%
- 15%-points
- TIR improvement, BL TIR ≥60%
- 5%-point
- Difference between subgroups
- P < 0.001
Original publication
Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes. Diabetes Technol Ther. Published 20 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →